Autoimmune diseaseImmunology & inflammationDermatology PopPKPKPDMIPD/TDM

Secukinumab exposure and PASI dynamics

Reference paper ↗

A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.

Therapeutic
Secukinumab
Modality
Monoclonal antibody
Target
IL17A, IL-17A
Disease
Moderate-to-severe plaque psoriasis
Model type
PopPK, PKPD, MIPD/TDM

Complete model workspace

Checking workspace access…

Parameters
14
States
13
Equations
13
Derived outputs
20

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Subject 1 300 mg every 4 weeks 20-cycle

How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance? Explore this intervention regimen through Central secukinumab concentration, PASI score, IL-17A pathway drug effect, Tolerance drive, Cumulative concentration exposure.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–616 day; step 7

InputDefaultAvailable range
Systemic clearance0.15 L/day0.075–0.225 L/day
Peripheral distribution volume3.72 L1.86–5.58 L
Absorption rate constant0.2 1/day0.1–0.3 1/day
Half-maximal inhibitory concentration9.35 mg/L4.675–14.02 mg/L
Maximum inhibitory effect1.17 dimensionless0.585–1.755 dimensionless

Expected readouts

Central secukinumab concentration · PASI score (dimensionless) · Il 17 a pathway drug effect · Tolerance drive · Cumulative concentration exposure (mg*day/L)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 14 declared model parameters.

More key parameters (1)

How the model represents the biology

A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.

How does secukinumab exposure drive delayed PASI response in the released scenarios?A subcutaneous secukinumab dose enters a depot, is absorbed into central exposure, and exchanges with a peripheral pool. Central concentration generates an empirical pathway-effect signal that passes through four delayed PASI stages. A structurally optional tolerance module is inactive or constant under current public scenarios.BIOLOGY OVERVIEWHow does secukinumab exposure drive delayed PASI response in the releasedscenarios?Subcutaneous doseSecukinumab inputSC depotBioavailable absorptionCentral exposureSecukinumab concentrationPeripheral poolReversible distributionEmpirical pathwayeffectConcentration-dependent ImaxsignalOptional toleranceInactive or constant publiclyDelayed PASI responseFour-stage turnover chainPRIMARY READOUTSCentral secukinumab concentrationCentral secukinumab concen…PASIPASIDrug-effect fractionDrug-effect fractionTolerance driveTolerance driveCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Explicit IL-17A concentration or binding, receptors, immune cells, and lesion biology are not represented; tolerance must not be interpreted as observed resistance in current public scenarios.

Modeled relationships (7)
  • Subcutaneous dose → SC depot: SC input (flow)
  • SC depot → Central exposure: absorption (flow)
  • Central exposure ↔ Peripheral pool: distribution (reversible exchange)
  • Central exposure → Empirical pathway effect: Imax effect (modulation)
  • Central exposure → Optional tolerance: optional drive (modulation)
  • Optional tolerance → Empirical pathway effect: optional scaling (modulation)
  • Empirical pathway effect → Delayed PASI response: four delays (modulation)

Modeled relationships: Subcutaneous dose to SC depot: SC input (flow); SC depot to Central exposure: absorption (flow); Central exposure reversibly exchanges with Peripheral pool: distribution (reversible exchange); Central exposure to Empirical pathway effect: Imax effect (modulation); Central exposure to Optional tolerance: optional drive (modulation); Optional tolerance to Empirical pathway effect: optional scaling (modulation); Empirical pathway effect to Delayed PASI response: four delays (modulation).

Primary readouts: Central secukinumab concentration; PASI; Drug-effect fraction; Tolerance drive; Cumulative exposure.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID rodriguez_fernandez_2024_secukinumab_psoriasis_mipd.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics